REN and heart failure: Renin–angiotensin–aldosterone-system-inhibitors (RAASi) are recommended as a class I indication for patients with heart failure with reduced ejection fraction (HFrEF) as part of guideline-directed medical therapy (GDMT), as they alleviate symptoms, reduce hospitalizations due to heart failure (HF), and enhance overall survival1–4.